Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort,Blood Cancer Journal

当前位置： X-MOL 学术 › Blood Cancer J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2024-09-30 , DOI: 10.1038/s41408-024-01150-3
Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Dam Andersen, Trine Engelbrecht Hybel, Mads Emil Bjørn, Pär Lars Josefsson, Lars Møller Pedersen, Maja Bech Juul, Robert Schou Pedersen, Michael Thorsgaard, Ida Blok Sillesen, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Paw Jensen, Charlotte Madsen, Maja Ludvigsen